Lysosomal Therapeutics

Mair Therapeutics

This biotechnology company develops small-molecule therapeutics targeting lysosomal ion channels for patients with neurodegenerative conditions such as Parkinson’s disease.

Mair Therapeutics

This biotechnology company develops small-molecule therapies targeting lysosomal ion channels to treat neurodegenerative disorders such as Parkinson's disease for patients and healthcare institutions.

NeurOdys Therapeutics

This biotechnology company develops small molecule therapies for patients with neurodegenerative conditions such as Alzheimer's and Parkinson's diseases.

Amplify Therapeutics

This biopharmaceutical company develops disease-modifying therapies for lysosomal Parkinson's disease and Gaucher disease to treat patients with specific genetic subgroups.

Yumanity Therapeutics

This company develops small molecule drugs to treat neurodegenerative diseases for patients with conditions such as Parkinson's disease and amyotrophic lateral sclerosis.

Polku Therapeutics Oy

This company develops small molecule therapies targeting neurodegenerative diseases for patients with conditions including Alzheimer's, Parkinson's and progressive supranuclear palsy.

Lyterian

This company develops small molecule therapeutics using protein homeostasis mechanisms to treat neurodegenerative and protein aggregation diseases for patients with unmet medical needs.

CuraSen Therapeutics

This biopharmaceutical company develops small molecule drugs to treat patients with neurodegenerative disorders, such as Parkinson's and Alzheimer's disease.